Metabolic syndrome

被引:7
作者
Boursier, V.
机构
[1] Hop St Joseph, Serv Med Vasc, F-75674 Paris 14, France
[2] Hop St Joseph, Serv Med Interne, F-75674 Paris 14, France
[3] Hop Tenon, Unite Med Vasc, F-75970 Paris 20, France
关键词
metabolic syndrome; insulin resistance; visceral obesity; adiponectin; type II diabetes;
D O I
10.1016/S0398-0499(06)76543-X
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Metabolic syndrome is public health problem. The characteristic feature is an association between factors contributing to increased cardiovascular risk. Several definitions have been proposed from 1998 to 2005. All proposed definitions take into consideration insulin resistance and its corollary hyperglycemia, overweight, hypertriglyceridemia, and LDL-cholesterol lowering. The most widely used definitions are proposed by the World Health Organization (WHO) and the American "Cholesterol" program (NCEP-ATPIII). The prevalence of metabolic syndrome varies by geographic region as a function of the chosen definition, the study methodology, the selection criteria, the age and gender of the study population, and the period of the study. Prevalence is higher in the United States than Europe and increases with age. A growing number of adolescents appear to meet the criteria of metabolic syndrome. Irrespective of the definition retained, metabolic syndrome is associated with increased cardiovascular risk and increased risk of type II diabetes. Sound evidence is however lacking on whether the risk is greater than that of taking into account each individual factor. Several points remain to be clarified concerning the underlying mechanisms. Visceral adipose tissue appears to be a key element in the process via anomalous function related to obesity and insulin resistance. Management is based mainly on reduction of body weight and regular physical activity. Drugs may be necessary to correct for the dyslipidemia, normalize blood glucose and reduce blood pressure.
引用
收藏
页码:190 / 201
页数:12
相关论文
共 56 条
[1]
RELATIONSHIPS OF GENERALIZED AND REGIONAL ADIPOSITY TO INSULIN SENSITIVITY IN MEN [J].
ABATE, N ;
GARG, A ;
PESHOCK, RM ;
STRAYGUNDERSEN, J ;
GRUNDY, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :88-98
[2]
*AFF SAPS, 2005, PRIS CHARG THER PAT
[3]
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[4]
2-S
[5]
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[6]
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[7]
*AM DIAB ASS, 2005, DIABETES CARE, V38, pS4
[8]
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[9]
The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome.: The French DESIR study [J].
Balkau, B ;
Vernay, M ;
Mhamdi, L ;
Novak, M ;
Arondel, D ;
Vol, S ;
Tichet, J ;
Eschwège, E .
DIABETES & METABOLISM, 2003, 29 (05) :526-532
[10]
Balkau B, 1999, DIABETIC MED, V16, P442